Â鶹´«Ã½¸ßÇå°æ

Anna Pavlick, BSN, MSc, DO, MBA is a medical oncologist with over 20 years of experience treating patients with skin cancer, including melanoma, basal cell cancer, squamous cell cancer and Merkel cell carcinoma. She is also an expert in treating ocular melanoma, eyelid tumors and other rare solid tumor malignancies, including a research interest in neurofibromatosis-1 (NF1) malignancies. She is currently accepting new patients for both in-office visits and telehealth appointments.Dr. Pavlick was recruited to Â鶹´«Ã½¸ßÇå°æ as Professor of Medicine in the Division of Hematology & Medical Oncology. She is the founding Director of the Cutaneous Oncology Program at Â鶹´«Ã½¸ßÇå°æ and NewYork-Presbyterian. Dr. Pavlick’s major research interests include investigating targeted therapies, combination therapies and immunotherapies. She also conducts outcomes research evaluating quality of life.Dr. Pavlick earned her medical degree from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School; her Master of Science in Human Anatomy from Fairleigh Dickinson University; and her Bachelor of Science in Biology and Nursing degree from Fairfield University. She completed an internal medicine residency at UMDNJ and hematology and oncology fellowship training at Memorial Sloan Kettering Cancer Center. In addition to her undergraduate and medical training, Dr. Pavlick graduated from the Drexel School of Medicine Executive Leadership in Academic Medicine in 2012 and earned her Master of Business Administration (MBA) degree from Columbia University Business School in 2017.Dr. Pavlick has authored and co-authored over 100 publications and presented her research at international meetings. She serves on the several editorial boards, including The Journal of Drugs in Dermatology and The Journal of ImmunoTherapeutics of Cancer (Associate Editor). She is a member of leading oncology societies including American Society of Clinical Oncology (ASCO), American Academy of Clinical Research (AACR), the Society for Melanoma Research, Society for Immunotherapy and Translational Research in Cancer and the European Society of Medical Oncology (ESMO).